Antidepressant pharmacotherapy helps some cigarette smokers more than others

Brian Hitsman, Atul Mahableshwarkar, Kathleen A. Segraves, Regina Pingitore, Bonnie Spring*, J. Scott Mizes, Jean L. Kristeller, Weichun Xu

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

89 Scopus citations

Abstract

Adult smokers (N = 253) without clinically significant depression were randomized on a double-blind basis to receive fluoxetine (30 or 60 mg daily) or a placebo for 10 weeks in combination with cognitive-behavioral therapy (CBT). It was predicted that fluoxetine would selectively benefit smokers with higher baseline depression, nicotine dependence, and weight concern and lower self-efficacy about quitting smoking. Among those who completed the prescribed treatment regimen, baseline depression scores moderated the treatment response. Logistic regression analyses showed that 1 and 3 months after the quit date, fluoxetine increased the likelihood of abstinence, as compared with placebo, among smokers with minor depression but not among those with little or no depression. Results suggest that, as an adjunct to CBT, fluoxetine enhances cessation by selectively benefiting medication- compliant smokers who display even subclinical levels of depression.

Original languageEnglish (US)
Pages (from-to)547-554
Number of pages8
JournalJournal of Consulting and Clinical Psychology
Volume67
Issue number4
DOIs
StatePublished - Aug 20 1999

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Antidepressant pharmacotherapy helps some cigarette smokers more than others'. Together they form a unique fingerprint.

Cite this